GRAIL Inc. Overview

GRAIL, Inc., a prominent player in the biotechnology sector, operates with a focus on early cancer detection. The company leverages a combination of science, technology, and clinical studies to identify cancer at its earliest stages. GRAIL’s services are primarily offered in the United States.

Financial Snapshot

As of August 10, 2025, GRAIL’s stock closed at $32.69 on the Nasdaq exchange. The company’s market capitalization stands at approximately $1.18 billion USD. Over the past year, GRAIL’s stock has experienced significant volatility, reaching a 52-week high of $63.99 on February 17, 2025, and a 52-week low of $12.33 on October 6, 2024.

Company Focus

GRAIL’s mission is centered around the early detection of cancer, aiming to improve patient outcomes through timely diagnosis. By integrating advanced scientific research with cutting-edge technology, GRAIL seeks to revolutionize cancer screening and detection processes.

Market Position

Operating within the health care sector, GRAIL is positioned as a key innovator in cancer diagnostics. The company’s efforts are directed towards making early cancer detection more accessible and effective, potentially transforming the landscape of cancer care.

Conclusion

GRAIL, Inc. continues to make strides in the biotechnology field, with a strong emphasis on early cancer detection. Despite recent stock fluctuations, the company’s commitment to advancing cancer diagnostics remains steadfast, positioning it as a significant player in the health care sector.